Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus - 19/06/14
Abstract |
Background |
Radiofrequency ablation (RFA) has become an accepted form of endoscopic treatment for Barrett's esophagus (BE), yet reported response rates are variable. There are no accepted quality measures for performing RFA, and provider-level characteristics may influence RFA outcomes.
Objective |
To determine whether endoscopist RFA volume is associated with rates of complete remission of intestinal metaplasia (CRIM) after RFA in patients with BE.
Design |
Retrospective analysis of longitudinal data.
Setting |
Three tertiary-care medical centers.
Patients |
Patients with BE treated with RFA.
Intervention |
RFA.
Main Outcome Measurements |
For each endoscopist, we recorded RFA volume, defined as the number of unique patients treated as well as corresponding CRIM rates. We calculated a Spearman correlation coefficient relating these 2 measures.
Results |
We identified 417 patients with BE treated with RFA who had at least 1 post-RFA endoscopy with biopsies. A total of 73% of the cases had pretreatment histology of high-grade dysplasia or adenocarcinoma. The procedures were performed by 7 endoscopists, who had a median RFA volume of 62 patients (range 20-188). The overall CRIM rate was 75.3% (provider range 62%-88%). The correlation between endoscopist RFA volume and CRIM rate was strong and significant (rho = 0.85; P = .014). In multivariable analysis, higher RFA volume was significantly associated with CRIM (P for trend .04).
Limitations |
Referral setting may limit generalizability. Limited number of endoscopists analyzed.
Conclusion |
Endoscopist RFA volume correlates with rates of successful BE eradication. Further studies are required to confirm these findings and to determine whether RFA volume is a valid predictor of treatment outcomes in BE.
Il testo completo di questo articolo è disponibile in PDF.Abbreviations : BE, CRIM, EAC, RFA
Mappa
| DISCLOSURE: This study was supported in part by the National Institutes of Health U54 award (C.J.L., J.M.P., G.G.G., G.W.F., M.D., P.G.I., L.L., K.K.W., J.A.A.; U54 CA163004) and a Career Development Award (J.A.A.; K07 CA132892) C. Lightdale is on the advisory board of CDx Diagnostics, received product royalties from Cook Medical, and is a consultant for Covidien. J. Poneros is a consultant for Boston Scientific. G. Ginsberg is a consultant for Olympus and CDx. P. Iyer received research funding from Takeda and is a consultant for Olympus. K. Wang received research support from Covidien, Pinnacle Pharmaceuticals, and CSA Medical. J. Abrams Received research support from Covidien, C2 Therapeutics, and Trio Medicines. No other financial relationships relevant to this publication were disclosed. |
|
| If you would like to chat with an author of this article, you may contact Dr Abrams at ja660@columbia.edu. |
Vol 80 - N° 1
P. 71-77 - luglio 2014 Ritorno al numero
Articolo precedente
- Consent: Can it be more informed?
- Andrew D. Feld
- Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance
- Yean Cheant Lim, Massimiliano di Pietro, Maria O'Donovan, Susan Richardson, Irene Debiram, Susan Dwerryhouse, Richard H. Hardwick, Marc Tischkowitz, Carlos Caldas, Krish Ragunath, Rebecca C. Fitzgerald
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?